Document ID: PC-MY-102220

Speaker: Prof. Jin-Hyoung Kang

Taking Cancer On Webinar – Let’s TOAST to Maximising Time on EGFR-TKI Therapy (Lecture)

Watch Prof. Jin-Hyoung Kang as he discusses how sequential approach with upfront GIOTRIF® (afatinib) is a feasible and cost-effective treatment strategy for EGFR M+ NSCLC patients.

Speaker

Prof. Jin-Hyoung Kang

Professor of Medicine, Seoul St. Mary’s Hospital
Director in Medical Oncology Program, The Catholic University of Korea
Seoul, South Korea

Error message

WEBINAR VIDEOS

Taking Cancer On Webinar – Let’s TOAST to Maximising Time on EGFR-TKI Therapy (Lecture)

Expert conversations

Speaker

MORE VIDEOS

Efficacy of EGFR-TKIs for Uncommon Mutations Q&A

6th SSO ASM Lung Track – Sequencing EGFR-TKIs in NSCLC Treatment

6th SSO ASM Lung Track – Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations

6th SSO ASM Lung Track – Evolving Treatment Landscape in EGFRm+ NSCLC

Taking Cancer On Webinar – Let’s TOAST to Maximising Time on EGFR-TKI Therapy (Q&A)